MX2023005301A - Compuestos dirigidos a brm y metodos de uso asociados. - Google Patents
Compuestos dirigidos a brm y metodos de uso asociados.Info
- Publication number
- MX2023005301A MX2023005301A MX2023005301A MX2023005301A MX2023005301A MX 2023005301 A MX2023005301 A MX 2023005301A MX 2023005301 A MX2023005301 A MX 2023005301A MX 2023005301 A MX2023005301 A MX 2023005301A MX 2023005301 A MX2023005301 A MX 2023005301A
- Authority
- MX
- Mexico
- Prior art keywords
- associated methods
- targeting compounds
- brm
- brm targeting
- binding moiety
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063110688P | 2020-11-06 | 2020-11-06 | |
| PCT/US2021/058424 WO2022099117A1 (en) | 2020-11-06 | 2021-11-08 | Brm targeting compounds and associated methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005301A true MX2023005301A (es) | 2023-07-18 |
Family
ID=81456756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005301A MX2023005301A (es) | 2020-11-06 | 2021-11-08 | Compuestos dirigidos a brm y metodos de uso asociados. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12448389B2 (enExample) |
| EP (1) | EP4240743A1 (enExample) |
| JP (1) | JP2023549341A (enExample) |
| KR (1) | KR20230117577A (enExample) |
| CN (1) | CN116745295A (enExample) |
| AU (1) | AU2021376415A1 (enExample) |
| CA (1) | CA3200685A1 (enExample) |
| IL (1) | IL302669A (enExample) |
| MX (1) | MX2023005301A (enExample) |
| WO (1) | WO2022099117A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115867554B (zh) * | 2020-06-09 | 2025-09-02 | 普莱鲁德疗法有限公司 | Brm靶向化合物和相关使用方法 |
| JP7723743B2 (ja) * | 2020-11-20 | 2025-08-14 | フォグホーン セラピューティクス インコーポレイテッド | 化合物及びその使用 |
| JP2024512501A (ja) | 2021-03-19 | 2024-03-19 | アルヴィナス・オペレーションズ・インコーポレイテッド | インダゾール系化合物及び関連使用方法 |
| CA3235512A1 (en) * | 2021-10-22 | 2023-04-27 | Xiaobao Yang | Crbn e3 ligase ligand compound, protein degrader developed based thereon and their applications |
| WO2023178181A1 (en) * | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| AU2023269778A1 (en) * | 2022-05-10 | 2024-12-12 | Prelude Therapeutics Incorporated | 6,6a,7,8,9,10-hexahydro-5h-pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazine derivatives as smarca4 protein degraders for the treatment of cancer |
| CN120282966A (zh) * | 2022-09-15 | 2025-07-08 | 普莱鲁德疗法有限公司 | Brm靶向化合物和相关使用方法 |
| JP2025538228A (ja) | 2022-11-15 | 2025-11-26 | プレリュード・セラピューティクス・インコーポレイテッド | Ｂｒｍ標的化化合物及び関連する使用方法 |
| WO2024192064A1 (en) * | 2023-03-14 | 2024-09-19 | Oncopia Therapeutics, Inc. D/B/A/ Proteovant Therapeutics, Inc. | Compounds and compositions as smarca2/4 degraders and uses thereof |
| WO2024208300A1 (zh) * | 2023-04-07 | 2024-10-10 | 南京再明医药有限公司 | Brm选择性降解剂化合物 |
| EP4695250A1 (en) | 2023-04-12 | 2026-02-18 | Aurigene Oncology Limited | Tetracyclic compounds as smarca2 and/or smarca4 degraders |
| EP4727541A2 (en) * | 2023-06-16 | 2026-04-22 | Plexium, Inc. | Compounds and pharmaceutical compositions that degrade swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a |
| TW202515874A (zh) | 2023-09-28 | 2025-04-16 | 美商亞文納營運公司 | 用於靶向降解富含白胺酸之重複激酶２（ｌｒｒｋ２）的基於苯并咪唑及苯并咪唑酮之ｐｒｏｔａｃ化合物 |
| WO2025101738A1 (en) * | 2023-11-07 | 2025-05-15 | Prelude Therapeutics Incorporated | Brm targeting compounds and associated methods of use |
| WO2025106472A1 (en) * | 2023-11-13 | 2025-05-22 | Regents Of The University Of Michigan | Compounds and compositions as smarca2/4 degraders and uses thereof |
| WO2025106482A1 (en) * | 2023-11-13 | 2025-05-22 | Oncopia Therapeutics, Inc. D/B/A Sk Life Science Labs | Compounds and compositions as smarca2/4 degraders and uses thereof |
| WO2025113460A1 (zh) * | 2023-11-28 | 2025-06-05 | 西藏海思科制药有限公司 | 一种哒嗪并三环衍生物及其在医药上的应用 |
| CN120548310A (zh) * | 2023-12-26 | 2025-08-26 | 标新生物医药科技(上海)有限公司 | 具有双氮杂环取代的异吲哚啉酮骨架的化合物及其应用 |
| WO2025184459A1 (en) * | 2024-03-01 | 2025-09-04 | Prelude Therapeutics Incorporated | Brm and brg1 targeting compounds and associated methods of use |
| US20250276074A1 (en) | 2024-03-01 | 2025-09-04 | Prelude Therapeutics Incorporated | Brm and brg1 targeting antibody-drug conjugates and methods of use thereof |
| WO2025194405A1 (en) * | 2024-03-21 | 2025-09-25 | Prelude Therapeutics Incorporated | Polymorphic smarca inhibitors and uses thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5040548A (en) | 1989-06-01 | 1991-08-20 | Yock Paul G | Angioplasty mehtod |
| US5350395A (en) | 1986-04-15 | 1994-09-27 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5061273A (en) | 1989-06-01 | 1991-10-29 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US4748982A (en) | 1987-01-06 | 1988-06-07 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| CA1322628C (en) | 1988-10-04 | 1993-10-05 | Richard A. Schatz | Expandable intraluminal graft |
| US6344053B1 (en) | 1993-12-22 | 2002-02-05 | Medtronic Ave, Inc. | Endovascular support device and method |
| US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
| US5292331A (en) | 1989-08-24 | 1994-03-08 | Applied Vascular Engineering, Inc. | Endovascular support device |
| WO2016105518A1 (en) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| GB2554071A (en) | 2016-09-14 | 2018-03-28 | Univ Dundee | Small molecules |
| CN110506039A (zh) | 2016-10-11 | 2019-11-26 | 阿尔维纳斯股份有限公司 | 用于雄激素受体靶向降解的化合物和方法 |
| BR112019011200B1 (pt) | 2016-12-01 | 2021-12-28 | Arvinas Operations, Inc | Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio |
| WO2019084026A1 (en) | 2017-10-24 | 2019-05-02 | Genentech, Inc. | (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE |
| WO2019084030A1 (en) | 2017-10-24 | 2019-05-02 | Genentech, Inc. | (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE |
| US20190300521A1 (en) | 2018-04-01 | 2019-10-03 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| EP3784665A4 (en) * | 2018-04-26 | 2022-01-26 | Aurigene Discovery Technologies Limited | PYRIDAZINE DERIVATIVES AS SMARCA2/4 DEGRADERS |
| US11771697B2 (en) * | 2018-04-30 | 2023-10-03 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of polybromo-1 (PBRM1) |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| MX2021004191A (es) | 2018-10-15 | 2021-05-27 | Nurix Therapeutics Inc | Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. |
| WO2021133917A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| CN115867554B (zh) | 2020-06-09 | 2025-09-02 | 普莱鲁德疗法有限公司 | Brm靶向化合物和相关使用方法 |
| AU2023269778A1 (en) * | 2022-05-10 | 2024-12-12 | Prelude Therapeutics Incorporated | 6,6a,7,8,9,10-hexahydro-5h-pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazine derivatives as smarca4 protein degraders for the treatment of cancer |
-
2021
- 2021-11-08 WO PCT/US2021/058424 patent/WO2022099117A1/en not_active Ceased
- 2021-11-08 KR KR1020237018973A patent/KR20230117577A/ko active Pending
- 2021-11-08 US US17/521,195 patent/US12448389B2/en active Active
- 2021-11-08 CN CN202180087475.7A patent/CN116745295A/zh active Pending
- 2021-11-08 EP EP21816605.6A patent/EP4240743A1/en active Pending
- 2021-11-08 CA CA3200685A patent/CA3200685A1/en active Pending
- 2021-11-08 JP JP2023527451A patent/JP2023549341A/ja active Pending
- 2021-11-08 IL IL302669A patent/IL302669A/en unknown
- 2021-11-08 MX MX2023005301A patent/MX2023005301A/es unknown
- 2021-11-08 AU AU2021376415A patent/AU2021376415A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021376415A9 (en) | 2025-01-09 |
| AU2021376415A1 (en) | 2023-06-22 |
| JP2023549341A (ja) | 2023-11-24 |
| EP4240743A1 (en) | 2023-09-13 |
| WO2022099117A1 (en) | 2022-05-12 |
| CN116745295A (zh) | 2023-09-12 |
| IL302669A (en) | 2023-07-01 |
| US20230083376A1 (en) | 2023-03-16 |
| CA3200685A1 (en) | 2022-05-12 |
| KR20230117577A (ko) | 2023-08-08 |
| US12448389B2 (en) | 2025-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005301A (es) | Compuestos dirigidos a brm y metodos de uso asociados. | |
| AU2021289730A8 (en) | BRM targeting compounds and associated methods of use | |
| MX2025005722A (es) | Compuestos dirigidos a brm y métodos de uso asociados | |
| WO2019241430A3 (en) | Antibody-oligonucleotide conjugates | |
| CA3149406A1 (en) | Novel anti-cldn18.2 antibodies | |
| IL268888B2 (en) | Multispecific binding proteins targeting CAIX, ANOI, MESOTLIN, TROP2, CEA, or CLAUDIN-18.2 | |
| MX2022011818A (es) | Metodos y composiciones para el direccionamiento de canceres de celulas t. | |
| EP3902839A4 (en) | 18.2 CLAUDINE BINDING FRACTIONS AND THEIR USES | |
| AU2018251801A8 (en) | Novel type VI CRISPR orthologs and systems | |
| EP4361261A3 (en) | Novel cas13b orthologues crispr enzymes and systems | |
| WO2023039424A3 (en) | Methods and compositions for modulating a genome | |
| WO2015151078A3 (en) | Hydrophilic linkers for conjugation | |
| WO2008112290A3 (en) | Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer | |
| MX2022007960A (es) | Nuevos anticuerpos anti-fgfr2b. | |
| MX2022015966A (es) | Anticuerpos y metodos para tratar enfermedades asociadas a claudina. | |
| WO2020260898A3 (en) | Novel cancer antigens and methods | |
| PH12020551080A1 (en) | Combination therapy for treating or preventing cancer | |
| WO2022232016A3 (en) | Chimeric receptors targeting adgre2 and/or clec12a and uses thereof | |
| MX2024015476A (es) | Compuestos dirigidos a kat6 con un resto de unión a ligasa de ubiquitina | |
| EP4335496A3 (en) | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds | |
| WO2021262731A3 (en) | Macrocyclic compounds and methods of use thereof | |
| MX2020007664A (es) | Terapia de combinacion para tratar o prevenir el cancer. | |
| MX2022011779A (es) | Combinacion herbicida. | |
| WO2024081738A3 (en) | Compositions, methods, and systems for dna modification | |
| WO2021024133A3 (en) | Biopharmacuetical compositions and related methods |